Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM-001
- Development stage
- Phase 2
- Lead developer
- LipoMedics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
LM-001 is a nanoparticle-based formulation of the cytotoxic agent paclitaxel, developed by LipoMedics. It utilizes a proprietary nanoparticle delivery system to improve the solubility and pharmacokinetic profile of paclitaxel, a microtubule stabilizer that inhibits cell division. In July 2016, LipoMedics licensed the sales and distribution rights for LM-001 in China to Hunan Fangsheng Pharmaceutical Co. Ltd. The product is described as an earlier candidate in LipoMedics' pipeline, suggesting it may be a predecessor to their newer nanoparticle platforms. While the licensing agreement implies a stage of development ready for commercialization in the Chinese market, formal clinical phase data for specific indications has not been widely disclosed.
- Other names
- paclitaxel nanoparticle
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)LDLR (Low-density lipoprotein receptor)
Beyond the preview
Go deeper on LM-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM-001.